Jacobs Levy Equity Management, Inc Bristol Myers Squibb CO Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $28.4 Million - $32.2 Million	-592,275 Reduced 95.91%	25,247 $1.37 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $1.36 Million - $1.63 Million	-28,140 Reduced 4.36%	617,522 $31.7 Million
Q3 2023 Nov 16, 2023	BUY	$57.89 - $64.73 $6.35 Million - $7.1 Million	109,676 Added 20.46%	645,662 $37.5 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $11.1 Million - $12.4 Million	174,766 Added 48.38%	535,986 $34.3 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $23.5 Million - $26.7 Million	358,222 Added 11948.7%	361,220 $25 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $205,303 - $243,107	2,998 New	2,998 $215,000
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $69.2 Million - $76.2 Million	-953,073 Reduced 97.09%	28,526 $2.2 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $488,766 - $586,074	-7,950 Reduced 0.8%	981,599 $71.7 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $47.1 Million - $54.9 Million	878,728 Added 792.93%	989,549 $61.7 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $19.4 Million - $22.8 Million	-328,369 Reduced 74.77%	110,821 $6.56 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $47.7 Million - $51.9 Million	-770,404 Reduced 63.69%	439,190 $29.3 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $71.6 Million - $80.5 Million	1,205,951 Added 33103.24%	1,209,594 $76.4 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $210,346 - $238,361	3,643 New	3,643 $226,000
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $624,780 - $692,339	-10,879 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$54.82 - $64.09 $205,575 - $240,337	3,750 Added 52.6%	10,879 $640,000
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $7.19 Million - $10.4 Million	-154,950 Reduced 95.6%	7,129 $397,000
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $54.1 Million - $70.5 Million	-1,098,522 Reduced 87.14%	162,079 $10.4 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $4.27 Million - $5.06 Million	99,756 Added 8.59%	1,260,601 $63.9 Million
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $9.87 Million - $10.9 Million	-221,194 Reduced 16.0%	1,160,845 $52.6 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $4.04 Million - $4.81 Million	89,430 Added 6.92%	1,382,039 $65.9 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $21.2 Million - $27.4 Million	433,820 Added 50.52%	1,292,609 $67.2 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $6.22 Million - $7.02 Million	112,770 Added 15.12%	858,789 $53.3 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $6.03 Million - $7.52 Million	119,430 Added 19.06%	746,019 $41.3 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $2.2 Million - $2.54 Million	36,780 Added 6.24%	626,589 $39.6 Million
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $34.2 Million - $37.3 Million	571,189 Added 3067.61%	589,809 $36.1 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $23,748 - $27,408	430 Added 2.36%	18,620 $1.19 Million
Q2 2017 Nov 09, 2017	BUY	N/A	18,190	18,190 $1.01 Million

Others Institutions Holding BMY

# of Institutions

2,532

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$10.9 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.18 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.38 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.51 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.53 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account